• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥厚型心肌病患者发生心源性猝死的危险因素。

Risk factors of sudden cardiac death in hypertrophic cardiomyopathy.

机构信息

Department of Cardiology, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.

Department of Cardiology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China.

出版信息

Curr Opin Cardiol. 2022 Jan 1;37(1):15-21. doi: 10.1097/HCO.0000000000000939.

DOI:10.1097/HCO.0000000000000939
PMID:34636345
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8654272/
Abstract

PURPOSE OF REVIEW

Hypertrophic cardiomyopathy (HCM) is one of the leading causes of sudden cardiac death (SCD) in younger people and athletes. It is crucial to identify the risk factors for SCD in individuals with HCM. This review, based on recent systematic literature studies, will focus on the risk factors for SCD in patients with HCM.

RECENT FINDINGS

An increasing number of studies have further explored the risk factors for SCD in patients with HCM, and new risk markers have emerged accordingly. In addition, more accurate SCD risk estimation and stratification methods have been proposed and continuously improved.

SUMMARY

The identification of independent risk factors for HCM-related SCD would likely contribute to risk stratification. However, it is difficult to predict SCD with absolute certainty, as the annual incidence of SCD in adult patients with HCM is approximately 1%. The review discusses the established risk factors, such as a family history of SCD, unexplained syncope and some new risk factors. Taken together, the findings of this review demonstrate that there is a need for further research on individual risk factors and that SCD risk stratification in HCM patients remains a clinical challenge.

摘要

目的综述

肥厚型心肌病(HCM)是年轻人和运动员心源性猝死(SCD)的主要原因之一。确定 HCM 患者发生 SCD 的危险因素至关重要。本综述基于最近的系统文献研究,将重点关注 HCM 患者发生 SCD 的危险因素。

最新发现

越来越多的研究进一步探讨了 HCM 患者发生 SCD 的危险因素,相应出现了新的危险标志物。此外,提出了并不断改进更准确的 SCD 风险评估和分层方法。

总结

识别与 HCM 相关 SCD 的独立危险因素可能有助于进行风险分层。然而,由于 HCM 成年患者的 SCD 年发生率约为 1%,因此很难对 SCD 进行绝对确定的预测。本综述讨论了已确立的危险因素,如 SCD 家族史、不明原因晕厥和一些新的危险因素。总之,本综述的研究结果表明,需要进一步研究个体危险因素,HCM 患者的 SCD 风险分层仍然是一个临床挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88a5/8654272/59732592941e/cocar-37-15-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88a5/8654272/59732592941e/cocar-37-15-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88a5/8654272/59732592941e/cocar-37-15-g001.jpg

相似文献

1
Risk factors of sudden cardiac death in hypertrophic cardiomyopathy.肥厚型心肌病患者发生心源性猝死的危险因素。
Curr Opin Cardiol. 2022 Jan 1;37(1):15-21. doi: 10.1097/HCO.0000000000000939.
2
Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy.验证 2014 年欧洲心脏病学会指南风险预测模型在肥厚型心肌病患者中的一级预防心源性猝死的应用。
Circ Arrhythm Electrophysiol. 2015 Aug;8(4):829-35. doi: 10.1161/CIRCEP.114.002553. Epub 2015 Apr 28.
3
Hypertrophic Cardiomyopathy-Related Sudden Cardiac Death in Young People in Ontario.安大略省年轻人肥厚型心肌病相关心源性猝死。
Circulation. 2019 Nov 19;140(21):1706-1716. doi: 10.1161/CIRCULATIONAHA.119.040271. Epub 2019 Oct 21.
4
Validation of the new American College of Cardiology/American Heart Association Guidelines for the risk stratification of sudden cardiac death in a large Mediterranean cohort with Hypertrophic Cardiomyopathy.新的美国心脏病学会/美国心脏协会指南在一个大型地中海肥厚型心肌病队列中对心源性猝死风险分层的验证。
Hellenic J Cardiol. 2022 Jan-Feb;63:15-21. doi: 10.1016/j.hjc.2021.06.005. Epub 2021 Jun 17.
5
Validation of the hypertrophic cardiomyopathy risk-sudden cardiac death calculator in Asians.验证肥厚型心肌病风险-心源性猝死计算器在亚洲人中的适用性。
Heart. 2019 Dec;105(24):1892-1897. doi: 10.1136/heartjnl-2019-315160. Epub 2019 Aug 5.
6
Temporal and Global Trends of the Incidence of Sudden Cardiac Death in Hypertrophic Cardiomyopathy.肥厚型心肌病患者心源性猝死发生率的时间和全球趋势。
JACC Clin Electrophysiol. 2022 Nov;8(11):1417-1427. doi: 10.1016/j.jacep.2022.07.012. Epub 2022 Sep 28.
7
Automated extraction of sudden cardiac death risk factors in hypertrophic cardiomyopathy patients by natural language processing.通过自然语言处理自动提取肥厚型心肌病患者心源性猝死的危险因素。
Int J Med Inform. 2019 Aug;128:32-38. doi: 10.1016/j.ijmedinf.2019.05.008. Epub 2019 May 13.
8
Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator.比较肥厚型心肌病和除颤器患者新的风险预测模型(HCM Risk-SCD)和经典风险因素对猝死的预测价值。
Europace. 2016 May;18(5):773-7. doi: 10.1093/europace/euv079. Epub 2015 Apr 7.
9
International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM).2014 年欧洲心脏病学会肥厚型心肌病猝死预防指南的国际外部验证研究(EVIDENCE-HCM)。
Circulation. 2018 Mar 6;137(10):1015-1023. doi: 10.1161/CIRCULATIONAHA.117.030437. Epub 2017 Nov 30.
10
Sudden cardiac death in patients with hypertrophic cardiomyopathy: from bench to bedside with an emphasis on genetic markers.肥厚型心肌病患者的心源性猝死:从实验室到临床,重点关注基因标志物
Clin Cardiol. 1995 Apr;18(4):189-98. doi: 10.1002/clc.4960180403.

引用本文的文献

1
Artificial Intelligence-enhanced Electrocardiography for Hypertrophic Cardiomyopathy Diagnosis: A Systematic Review and Meta-analysis.人工智能增强心电图用于肥厚型心肌病诊断:一项系统评价和荟萃分析。
J Saudi Heart Assoc. 2025 May 18;37(2):8. doi: 10.37616/2212-5043.1431. eCollection 2025.
2
Mid-ventricular hypertrophic cardiomyopathy with apical aneurysm: a multimodality imaging case report.伴有心尖部动脉瘤的心室中部肥厚型心肌病:一例多模态影像学病例报告
Arch Peru Cardiol Cir Cardiovasc. 2025 Feb 12;6(1):44-48. doi: 10.47487/apcyccv.v6i1.452. eCollection 2025 Jan-Mar.
3
Arrhythmias and Sudden Death: What is New in Hypertrophic Cardiomyopathy?
心律失常与猝死:肥厚型心肌病有哪些新进展?
Card Fail Rev. 2025 Apr 1;11:e08. doi: 10.15420/cfr.2024.38. eCollection 2025.
4
The clinical and genetic spectrum of pediatric hypertrophic cardiomyopathy manifesting before one year of age.1岁前表现出的小儿肥厚型心肌病的临床和遗传谱系。
Pediatr Res. 2025 Mar 18. doi: 10.1038/s41390-025-03989-z.
5
Myocardial dysfunction caused by MyBPC3 P459fs mutation in hypertrophic cardiomyopathy: evidence from multi-omics approaches and super-resolution imaging.肥厚型心肌病中MyBPC3 P459fs突变引起的心肌功能障碍:来自多组学方法和超分辨率成像的证据
Front Cardiovasc Med. 2025 Feb 27;12:1529921. doi: 10.3389/fcvm.2025.1529921. eCollection 2025.
6
Mexican guidelines 2024 for the diagnosis and treatment of hypertrophic cardiomyopathy.《2024年墨西哥肥厚型心肌病诊断与治疗指南》
Arch Cardiol Mex. 2024;94(Supl 4):1-75. doi: 10.24875/ACM.M25000098.
7
Pathogenic genes and clinical prognosis in hypertrophic cardiomyopathy.肥厚型心肌病的致病基因与临床预后
World J Cardiol. 2025 Jan 26;17(1):99595. doi: 10.4330/wjc.v17.i1.99595.
8
Hypertrophic Cardiomyopathy with Special Focus on Mavacamten and Its Future in Cardiology.肥厚型心肌病:特别关注马伐卡坦及其在心脏病学领域的未来发展
Biomedicines. 2024 Nov 24;12(12):2675. doi: 10.3390/biomedicines12122675.
9
Pathological Alterations in Heart Mitochondria in a Rat Model of Isoprenaline-Induced Myocardial Injury and Their Correction with Water-Soluble Taxifolin.应激性心肌损伤大鼠模型中心脏线粒体的病理改变及其水溶性金雀异黄素的纠正作用。
Int J Mol Sci. 2024 Oct 29;25(21):11596. doi: 10.3390/ijms252111596.
10
Impact of Genetic Testing on the Diagnosis, Management, and Prognosis of Hypertrophic Cardiomyopathy: A Systematic Review.基因检测对肥厚型心肌病诊断、管理及预后的影响:一项系统评价
Cureus. 2024 Oct 7;16(10):e70993. doi: 10.7759/cureus.70993. eCollection 2024 Oct.